Intrinsic value of Editas Medicine - EDIT

Previous Close

$26.90

  Intrinsic Value

$1.10

stock screener

  Rating & Target

str. sell

-96%

Previous close

$26.90

 
Intrinsic value

$1.10

 
Up/down potential

-96%

 
Rating

str. sell

We calculate the intrinsic value of EDIT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.3

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  22
  34
  51
  74
  104
  143
  192
  252
  324
  409
  508
  621
  749
  891
  1,047
  1,218
  1,403
  1,602
  1,815
  2,040
  2,279
  2,530
  2,793
  3,069
  3,357
  3,658
  3,971
  4,296
  4,635
  4,986
Variable operating expenses, $m
  85
  131
  196
  284
  401
  551
  739
  971
  1,249
  1,578
  1,960
  2,396
  2,888
  3,436
  4,040
  4,699
  5,413
  6,180
  7,000
  7,870
  8,789
  9,758
  10,774
  11,838
  12,949
  14,108
  15,315
  16,570
  17,876
  19,233
Fixed operating expenses, $m
  84
  86
  88
  89
  91
  93
  95
  98
  100
  102
  104
  106
  109
  111
  114
  116
  119
  121
  124
  127
  130
  132
  135
  138
  141
  144
  148
  151
  154
  158
Total operating expenses, $m
  169
  217
  284
  373
  492
  644
  834
  1,069
  1,349
  1,680
  2,064
  2,502
  2,997
  3,547
  4,154
  4,815
  5,532
  6,301
  7,124
  7,997
  8,919
  9,890
  10,909
  11,976
  13,090
  14,252
  15,463
  16,721
  18,030
  19,391
Operating income, $m
  -147
  -183
  -233
  -300
  -388
  -501
  -643
  -817
  -1,025
  -1,271
  -1,556
  -1,881
  -2,248
  -2,656
  -3,106
  -3,597
  -4,128
  -4,699
  -5,309
  -5,956
  -6,640
  -7,360
  -8,116
  -8,907
  -9,733
  -10,595
  -11,492
  -12,425
  -13,395
  -14,404
EBITDA, $m
  -142
  -176
  -223
  -286
  -368
  -474
  -607
  -769
  -963
  -1,193
  -1,458
  -1,762
  -2,105
  -2,486
  -2,906
  -3,364
  -3,860
  -4,393
  -4,962
  -5,566
  -6,204
  -6,876
  -7,582
  -8,320
  -9,091
  -9,895
  -10,732
  -11,603
  -12,509
  -13,450
Interest expense (income), $m
  0
  2
  -1
  2
  7
  12
  20
  30
  42
  58
  76
  98
  123
  152
  184
  220
  260
  304
  351
  401
  455
  513
  574
  637
  704
  775
  848
  924
  1,004
  1,087
  1,173
Earnings before tax, $m
  -149
  -182
  -235
  -306
  -401
  -522
  -673
  -859
  -1,083
  -1,347
  -1,653
  -2,004
  -2,400
  -2,840
  -3,326
  -3,857
  -4,432
  -5,050
  -5,710
  -6,412
  -7,153
  -7,934
  -8,753
  -9,612
  -10,508
  -11,443
  -12,416
  -13,429
  -14,482
  -15,577
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -149
  -182
  -235
  -306
  -401
  -522
  -673
  -859
  -1,083
  -1,347
  -1,653
  -2,004
  -2,400
  -2,840
  -3,326
  -3,857
  -4,432
  -5,050
  -5,710
  -6,412
  -7,153
  -7,934
  -8,753
  -9,612
  -10,508
  -11,443
  -12,416
  -13,429
  -14,482
  -15,577

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  115
  178
  266
  386
  544
  748
  1,004
  1,318
  1,696
  2,142
  2,660
  3,252
  3,920
  4,664
  5,484
  6,379
  7,348
  8,389
  9,502
  10,683
  11,931
  13,246
  14,625
  16,069
  17,578
  19,151
  20,789
  22,493
  24,265
  26,107
Adjusted assets (=assets-cash), $m
  115
  178
  266
  386
  544
  748
  1,004
  1,318
  1,696
  2,142
  2,660
  3,252
  3,920
  4,664
  5,484
  6,379
  7,348
  8,389
  9,502
  10,683
  11,931
  13,246
  14,625
  16,069
  17,578
  19,151
  20,789
  22,493
  24,265
  26,107
Revenue / Adjusted assets
  0.191
  0.191
  0.192
  0.192
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
  0.191
Average production assets, $m
  63
  97
  145
  210
  296
  407
  547
  718
  923
  1,166
  1,448
  1,771
  2,135
  2,540
  2,986
  3,474
  4,001
  4,568
  5,174
  5,817
  6,497
  7,213
  7,964
  8,750
  9,572
  10,428
  11,320
  12,248
  13,213
  14,216
Working capital, $m
  -41
  -63
  -95
  -138
  -194
  -267
  -358
  -470
  -605
  -764
  -949
  -1,160
  -1,399
  -1,664
  -1,957
  -2,276
  -2,622
  -2,993
  -3,390
  -3,811
  -4,257
  -4,726
  -5,218
  -5,733
  -6,272
  -6,833
  -7,417
  -8,025
  -8,658
  -9,315
Total debt, $m
  -13
  43
  122
  230
  373
  556
  787
  1,069
  1,410
  1,811
  2,277
  2,810
  3,411
  4,081
  4,819
  5,624
  6,497
  7,434
  8,435
  9,498
  10,621
  11,804
  13,046
  14,346
  15,703
  17,119
  18,593
  20,127
  21,722
  23,380
Total liabilities, $m
  103
  160
  239
  347
  490
  673
  903
  1,186
  1,526
  1,928
  2,394
  2,927
  3,528
  4,197
  4,935
  5,741
  6,613
  7,551
  8,551
  9,614
  10,738
  11,921
  13,163
  14,462
  15,820
  17,236
  18,710
  20,244
  21,839
  23,497
Total equity, $m
  11
  18
  27
  39
  54
  75
  100
  132
  170
  214
  266
  325
  392
  466
  548
  638
  735
  839
  950
  1,068
  1,193
  1,325
  1,463
  1,607
  1,758
  1,915
  2,079
  2,249
  2,427
  2,611
Total liabilities and equity, $m
  114
  178
  266
  386
  544
  748
  1,003
  1,318
  1,696
  2,142
  2,660
  3,252
  3,920
  4,663
  5,483
  6,379
  7,348
  8,390
  9,501
  10,682
  11,931
  13,246
  14,626
  16,069
  17,578
  19,151
  20,789
  22,493
  24,266
  26,108
Debt-to-equity ratio
  -1.150
  2.430
  4.610
  5.970
  6.850
  7.440
  7.840
  8.110
  8.310
  8.450
  8.560
  8.640
  8.700
  8.750
  8.790
  8.820
  8.840
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.930
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -149
  -182
  -235
  -306
  -401
  -522
  -673
  -859
  -1,083
  -1,347
  -1,653
  -2,004
  -2,400
  -2,840
  -3,326
  -3,857
  -4,432
  -5,050
  -5,710
  -6,412
  -7,153
  -7,934
  -8,753
  -9,612
  -10,508
  -11,443
  -12,416
  -13,429
  -14,482
  -15,577
Depreciation, amort., depletion, $m
  4
  6
  10
  14
  20
  27
  37
  48
  62
  78
  97
  119
  143
  170
  200
  233
  269
  307
  347
  390
  436
  484
  534
  587
  642
  700
  760
  822
  887
  954
Funds from operations, $m
  -145
  -175
  -225
  -292
  -381
  -494
  -637
  -811
  -1,021
  -1,269
  -1,556
  -1,885
  -2,256
  -2,670
  -3,126
  -3,624
  -4,164
  -4,744
  -5,363
  -6,021
  -6,717
  -7,450
  -8,219
  -9,024
  -9,866
  -10,743
  -11,656
  -12,607
  -13,595
  -14,623
Change in working capital, $m
  -15
  -22
  -31
  -43
  -57
  -73
  -91
  -112
  -135
  -159
  -185
  -211
  -238
  -265
  -293
  -319
  -346
  -372
  -397
  -421
  -445
  -469
  -492
  -515
  -538
  -561
  -584
  -608
  -632
  -657
Cash from operations, $m
  -129
  -153
  -194
  -250
  -324
  -422
  -545
  -699
  -886
  -1,109
  -1,371
  -1,674
  -2,018
  -2,405
  -2,833
  -3,305
  -3,818
  -4,372
  -4,966
  -5,600
  -6,271
  -6,981
  -7,727
  -8,509
  -9,327
  -10,182
  -11,072
  -11,999
  -12,963
  -13,966
Maintenance CAPEX, $m
  -3
  -4
  -6
  -10
  -14
  -20
  -27
  -37
  -48
  -62
  -78
  -97
  -119
  -143
  -170
  -200
  -233
  -269
  -307
  -347
  -390
  -436
  -484
  -534
  -587
  -642
  -700
  -760
  -822
  -887
New CAPEX, $m
  -23
  -34
  -48
  -65
  -86
  -111
  -139
  -171
  -206
  -243
  -282
  -322
  -364
  -405
  -447
  -487
  -528
  -567
  -606
  -643
  -680
  -716
  -751
  -786
  -821
  -857
  -892
  -928
  -965
  -1,003
Cash from investing activities, $m
  -26
  -38
  -54
  -75
  -100
  -131
  -166
  -208
  -254
  -305
  -360
  -419
  -483
  -548
  -617
  -687
  -761
  -836
  -913
  -990
  -1,070
  -1,152
  -1,235
  -1,320
  -1,408
  -1,499
  -1,592
  -1,688
  -1,787
  -1,890
Free cash flow, $m
  -155
  -191
  -248
  -325
  -425
  -552
  -712
  -907
  -1,140
  -1,414
  -1,732
  -2,094
  -2,501
  -2,953
  -3,450
  -3,993
  -4,579
  -5,208
  -5,878
  -6,590
  -7,342
  -8,133
  -8,962
  -9,830
  -10,736
  -11,681
  -12,664
  -13,687
  -14,750
  -15,855
Issuance/(repayment) of debt, $m
  -54
  56
  79
  108
  143
  183
  230
  283
  340
  402
  466
  533
  601
  670
  738
  806
  872
  937
  1,001
  1,063
  1,124
  1,183
  1,242
  1,300
  1,358
  1,416
  1,474
  1,534
  1,595
  1,658
Issuance/(repurchase) of shares, $m
  245
  188
  244
  318
  417
  542
  699
  891
  1,121
  1,392
  1,705
  2,063
  2,466
  2,915
  3,408
  3,947
  4,529
  5,154
  5,821
  6,530
  7,278
  8,065
  8,891
  9,756
  10,659
  11,600
  12,580
  13,600
  14,659
  15,761
Cash from financing (excl. dividends), $m  
  191
  244
  323
  426
  560
  725
  929
  1,174
  1,461
  1,794
  2,171
  2,596
  3,067
  3,585
  4,146
  4,753
  5,401
  6,091
  6,822
  7,593
  8,402
  9,248
  10,133
  11,056
  12,017
  13,016
  14,054
  15,134
  16,254
  17,419
Total cash flow (excl. dividends), $m
  36
  53
  75
  102
  134
  173
  217
  267
  321
  379
  440
  503
  567
  631
  696
  760
  823
  884
  944
  1,002
  1,060
  1,116
  1,171
  1,226
  1,280
  1,335
  1,390
  1,447
  1,504
  1,563
Retained Cash Flow (-), $m
  -245
  -188
  -244
  -318
  -417
  -542
  -699
  -891
  -1,121
  -1,392
  -1,705
  -2,063
  -2,466
  -2,915
  -3,408
  -3,947
  -4,529
  -5,154
  -5,821
  -6,530
  -7,278
  -8,065
  -8,891
  -9,756
  -10,659
  -11,600
  -12,580
  -13,600
  -14,659
  -15,761
Prev. year cash balance distribution, $m
  292
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  84
  -135
  -169
  -217
  -282
  -369
  -482
  -624
  -800
  -1,013
  -1,266
  -1,561
  -1,900
  -2,283
  -2,712
  -3,187
  -3,707
  -4,270
  -4,878
  -5,527
  -6,218
  -6,949
  -7,720
  -8,530
  -9,378
  -10,265
  -11,190
  -12,153
  -13,155
  -14,198
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  80
  -124
  -147
  -178
  -219
  -268
  -325
  -390
  -460
  -531
  -601
  -666
  -722
  -767
  -796
  -810
  -806
  -786
  -751
  -702
  -643
  -577
  -506
  -434
  -365
  -299
  -240
  -188
  -144
  -107
Current shareholders' claim on cash, %
  50.0
  13.6
  4.2
  1.4
  0.5
  0.2
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

FINANCIAL RATIOS  of  Editas Medicine (EDIT)

Valuation Ratios
P/E Ratio -9.9
Price to Sales 160.6
Price to Book 7.1
Price to Tangible Book
Price to Cash Flow -19.3
Price to Free Cash Flow -18.2
Growth Rates
Sales Growth Rate 200%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 200%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 19
Current Ratio 0
LT Debt to Equity 25.9%
Total Debt to Equity 33.3%
Interest Coverage 0
Management Effectiveness
Return On Assets -51.3%
Ret/ On Assets - 3 Yr. Avg. -114%
Return On Total Capital -65.3%
Ret/ On T. Cap. - 3 Yr. Avg. -248.3%
Return On Equity -77%
Return On Equity - 3 Yr. Avg. -252.2%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -1600%
EBITDA Margin - 3 Yr. Avg. -1750%
Operating Margin -1616.7%
Oper. Margin - 3 Yr. Avg. -1122.2%
Pre-Tax Margin -1616.7%
Pre-Tax Margin - 3 Yr. Avg. -1755.6%
Net Profit Margin -1616.7%
Net Profit Margin - 3 Yr. Avg. -1755.6%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

EDIT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EDIT stock intrinsic value calculation we used $13.728 million for the last fiscal year's total revenue generated by Editas Medicine. The default revenue input number comes from 0001 income statement of Editas Medicine. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EDIT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EDIT is calculated based on our internal credit rating of Editas Medicine, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Editas Medicine.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EDIT stock the variable cost ratio is equal to 385.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $82 million in the base year in the intrinsic value calculation for EDIT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Editas Medicine.

Corporate tax rate of 27% is the nominal tax rate for Editas Medicine. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EDIT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EDIT are equal to 285.1%.

Life of production assets of 14.9 years is the average useful life of capital assets used in Editas Medicine operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EDIT is equal to -186.8%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $208.08 million for Editas Medicine - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 47.204 million for Editas Medicine is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Editas Medicine at the current share price and the inputted number of shares is $1.3 billion.

RELATED COMPANIES Price Int.Val. Rating
SGMO Sangamo Therap 9.51 3.03  str.sell
BLUE bluebird bio 116.49 7.95  str.sell
NTLA Intellia Thera 17.01 2.46  str.sell
ABEO Abeona Therape 7.50 0.83  str.sell
CLLS Cellectis ADR 24.40 2.72  str.sell
AGTC Applied Geneti 6.83 4.15  hold
RGNX REGENXBIO 59.01 1.29  str.sell

COMPANY NEWS

▶ Cambridge's Editas asks FDA to start gene editing trial   [07:46PM  American City Business Journals]
▶ Editas: 3Q Earnings Snapshot   [06:03PM  Associated Press]
▶ Better Buy: Crispr Therapeutics AG vs. Editas   [Oct-09-18 04:35PM  Motley Fool]
▶ Who Owns Most Of Editas Medicine Inc (NASDAQ:EDIT)?   [Sep-25-18 01:58PM  Simply Wall St.]
▶ Crispr Appears 'Crispy and Overcooked,' Says Analyst   [Sep-21-18 11:23AM  Bloomberg]
▶ Is CRISPR Therapeutics AG a Buy?   [Sep-16-18 08:31AM  Motley Fool]
▶ Here's Why CRISPR Stocks Rose as Much as 18.7% in August   [Sep-04-18 11:29AM  Motley Fool]
▶ 3 Stocks Your Children Will Brag About Someday   [Aug-28-18 06:50PM  Motley Fool]
▶ Gene Editing is a Major Technology to Watch   [01:12PM  InvestorPlace]
▶ 3 Relatively Safe Ways to Invest in Gene Editing   [Aug-24-18 08:16AM  Motley Fool]
▶ Editas Prepares for the Commercialization of EDIT-101   [Aug-09-18 04:17PM  Motley Fool]
▶ Editas: 2Q Earnings Snapshot   [05:06PM  Associated Press]
▶ 3 Top Healthcare Stocks to Buy Right Now   [Jul-28-18 04:20PM  Motley Fool]
▶ Here's Why CRISPR Stocks Are Down as Much as 11.4% Today   [Jul-24-18 04:06PM  Motley Fool]
▶ Yet Another CRISPR Worry: What Should Investors Do?   [Jul-17-18 03:01PM  Motley Fool]
▶ [$$] New Research Prompts Selloff in Companies Using Crispr Technology   [Jul-16-18 07:31PM  The Wall Street Journal]
▶ Is Gene Editing Dangerous? 4 Things You Should Know   [Jun-18-18 02:22PM  Motley Fool]
▶ [$$] Gene-Editing Selloff Is Overdone   [Jun-16-18 12:01AM  Barrons.com]
▶ Here's Why CRISPR Stocks are Getting Rocked Today   [Jun-11-18 04:57PM  Motley Fool]
▶ 3 Stocks That Could Put Apple's Returns to Shame   [Jun-07-18 08:00AM  Motley Fool]
▶ What Makes This CRISPR Stock Better Than the Rest?   [May-30-18 03:37PM  Motley Fool]
▶ CRISPR Stocks Deserve a Second Look. Here's Why.   [May-16-18 07:00AM  Investopedia]
▶ [$$] Gene-Editing Pioneers Back Beam Therapeutics   [May-14-18 07:30AM  The Wall Street Journal]
▶ Your Guide to Investing in Gene Editing   [May-11-18 07:20PM  Motley Fool]
▶ 3 Growth Stocks for In-the-Know Investors   [08:09AM  Motley Fool]
▶ Editas: 1Q Earnings Snapshot   [May-03-18 05:50PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.